Camidanlumab tesirine for relapsed or refractory classic Hodgkin lymphoma: a phase 2 study.
Herrera AF, Ansell SM, Zinzani PL, Radford J, Maddocks K, Pinto A, Collins GP, Bachanova V, Bartlett NL, Bence-Bruckler I, Hamadani M, Kline J, Mayer J, Savage KJ, Advani RH, Caimi PF, Casasnovas RO, Feldman T, Hess B, Bastos-Oreiro M, Iyengar S, Szomor Á, Townsend W, André M, Dyczkowski J, Havenith K, Toukam M, Pantano S, Cruz HG, Wang L, Negievich Y, Lucero M, Wuerthner J, Carlo-Stella C.
Herrera AF, et al.
Blood Adv. 2025 Dec 9;9(23):6205-6217. doi: 10.1182/bloodadvances.2024015600.
Blood Adv. 2025.
PMID: 40811783
Clinical Trial.